Symbol="SPRO"
AssetType="Common Stock"
Name="Spero Therapeutics Inc"
Description="Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts."
CIK="1701108"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="73601000"
EBITDA="-13794000"
PERatio="None"
PEGRatio="0"
BookValue="1.448"
DividendPerShare="0"
DividendYield="0"
EPS="-0.46"
RevenuePerShareTTM="1.424"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.0706"
ReturnOnEquityTTM="-0.422"
RevenueTTM="53509000"
GrossProfitTTM="-42107000"
DilutedEPSTTM="-0.46"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="6.33"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="9.99"
PriceToBookRatio="2.757"
EVToRevenue="2.605"
EVToEBITDA="-0.475"
Beta="0.877"
num_52WeekHigh="3.18"
num_52WeekLow="0.712"
num_50DayMovingAverage="1.538"
num_200DayMovingAverage="1.695"
SharesOutstanding="52572000"
DividendDate="None"
ExDividendDate="None"
symbol="SPRO"
open="1.47"
high="1.48"
low="1.36"
price="1.40"
volume="453983.00"
latest_trading_day="2023-08-11"
previous_close="1.45"
change="-0.05"
change_percent="-3.4483%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="63"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="37"
Volume_recent_avg="426552"
Change_recent_avg="0.01"
Delta_recent_avg="0.08"
Variance_recent_avg="0.04"
Change_ratio_recent_avg="-0.08"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="37"
Aroon_momentum_negative="63"
image_negative_thumbnail_id_1="175"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0001.jpeg"
image_negative_thumbnail_id_2="107"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0069.jpeg"
image_neutral_thumbnail_id_1="524"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0075.jpeg"
image_neutral_thumbnail_id_2="589"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0010.jpeg"
image_positive_thumbnail_id_1="620"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0088.jpeg"
image_positive_thumbnail_id_2="691"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0017.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1188"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0022.jpeg"
